November 28, 2016 - By Louis Casey · 0 Comments
The stock of Biolinerx Limited Ads (NASDAQ:BLRX) registered a decrease of 1.76% in short interest. BLRX’s total short interest was 173,100 shares in November as published by FINRA. Its down 1.76% from 176,200 shares, reported previously. With 94,700 shares average volume, it will take short sellers 2 days to cover their BLRX’s short positions. The short interest to Biolinerx Limited Ads’s float is 0.39%. The stock increased 4.60% or $0.05 on November 25, hitting $1.09. Bioline RX Ltd (NASDAQ:BLRX) has risen 10.20% since April 25, 2016 and is uptrending. It has outperformed by 4.19% the S&P500.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has a market cap of $61.59 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.
Out of 3 analysts covering BioLineRx (NASDAQ:BLRX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $7 is the highest target while $3 is the lowest. The $5 average target is 358.72% above today’s ($1.09) stock price. BioLineRx has been the topic of 3 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by Maxim Group on Friday, August 12. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Buy” rating by TH Capital on Monday, July 27.
More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Prnewswire.com which released: “BioLineRx Reports Third Quarter 2016 Financial Results” on November 22, 2016, also Prnewswire.com with their article: “BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture …” published on August 25, 2016, Marketwatch.com published: “BioLine RX stock price target cut to $1 from $4 at Maxim Group” on June 02, 2011. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Streetinsider.com and their article: “BioLineRx (BLRX) Enters In-Licensing Agreement for Anti-Inflammatory DES Treatment” published on November 21, 2016 as well as Prnewswire.com‘s news article titled: “BioLineRx to Report Third Quarter Results on November 22, 2016” with publication date: November 15, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey